Liminatus Pharma, Inc. (LIMN) Form 8-K — May 20, 2026
Liminatus Pharma, Inc. (LIMN) announced on May 17, 2026, that it entered into a definitive merger agreement to acquire InnocsAI LLC, a developer of CAR-T and antibody therapies for oncology. The transaction is structured as a reverse merger where InnocsAI will merge into a subsidiary of Liminatus, with Liminatus continuing as the surviving public entity. Existing members of InnocsAI will receive 1.6 billion shares of Liminatus common stock at an issue price of $0.20 per share, valuing the equity consideration at approximately $320 million.
Key figures
- Offering Price
- 0.2
- Shares Offered
- 1600000000
- Closing payment shares
- 1600000000
- Contingent value rights percent
- 20
Price after filing
Close on the filing date to close N calendar days later (from $0.19). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.